What changed in Insmed Inc's latest annual report
In the year ended 31 Dec 2025, Insmed Inc's revenue rose 66.7% to USD 606.42m, from USD 363.71m; shareholders' equity rose 158.9% to USD 738.98m, from USD 285.38m; long-term debt fell 51% to USD 540.96m, from USD 1.10bn.
Year ended 31 Dec 2025. Source: 10-K filed 19 Feb 2026, read it on SEC EDGAR.
USD 363.71m to USD 606.42m
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 363.71m | 606.42m | Up 66.7% |
| Net income | -913.77m | -1.28bn | Not comparable |
| Total assets | 2.03bn | 2.26bn | Up 11.8% |
| Total liabilities | 1.74bn | 1.53bn | Down 12.3% |
| Long-term debt | 1.10bn | 540.96m | Down 51% |
| Cash and cash equivalents | 555.03m | 510.44m | Down 8% |
| Shareholders' equity | 285.38m | 738.98m | Up 158.9% |
Questions people ask
Did Insmed Inc's revenue grow last year?
Revenue grew 66.7%, from USD 363.71m to USD 606.42m in the year ended 31 Dec 2025.
Is Insmed Inc profitable?
Not in its latest year: it reported a net loss of USD 1.28bn in the year ended 31 Dec 2025. The year before: a net loss of USD 913.77m.
How much cash and debt does Insmed Inc have?
At its latest year end (31 Dec 2025), Insmed Inc reported cash and cash equivalents of USD 510.44m and long-term debt of USD 540.96m.
Where do these numbers come from?
From Insmed Inc's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Insmed Inc?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%